Bio-Techne Corporation (TECH) Key Metrics
TECH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $11.38B
- Enterprise value
- $11.40B
- P/E (TTM)
- 62.6 10-yr median 59.0
- Forward P/E
- 34.6
- PEG ratio
- 2.11
- Price / sales
- 9.4 10-yr median 10.6
- Price / book
- 5.4 10-yr median 6.1
- EV / EBITDA
- 32.8 10-yr median 33.5
- Dividend yield
- 0.44% $0.32 a year
- Beta
- 1.29
TECH key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsTECH valuation Price multiples at each fiscal year-end price.
TECH returns How much profit the business earns on the capital it uses.
TECH per-share figures Results divided by the shares outstanding at year-end.
TECH financial health Debt, liquidity and how easily interest is covered.
TECH efficiency & capital use Working capital cycle and where the cash goes.
TECH valuation history
TECH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TECH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TECH cash returned to shareholders
TECH price vs earnings per share
TECH key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $11.09B | $8.22B | $11.52B | $13.21B | $14.22B | $18.23B | $10.40B | $8.11B | $5.63B | $4.41B |
| Enterprise value | $11.12B | $8.50B | $11.79B | $13.46B | $14.30B | $18.42B | $10.57B | $8.45B | $5.80B | $4.60B |
| P/E ratio | 61.0 | 112.0 | 68.5 | 46.3 | 52.3 | 129.8 | 45.4 | 84.4 | 44.9 | 57.0 |
| Price / sales | 9.1 | 6.7 | 9.9 | 11.6 | 12.9 | 19.6 | 14.1 | 11.4 | 8.8 | 7.8 |
| Price / book | 5.3 | 4.3 | 5.6 | 6.7 | 8.4 | 11.7 | 7.5 | 7.0 | 5.2 | 4.6 |
| Price / free cash flow | 42.1 | 32.0 | 48.8 | 61.1 | 50.7 | 59.2 | 67.8 | 51.9 | 37.7 | 34.4 |
| Price / operating cash flow | 38.0 | 28.6 | 38.5 | 51.9 | 43.7 | 51.8 | 50.7 | 44.6 | 33.0 | 30.7 |
| EV / sales | 9.1 | 7.0 | 10.2 | 11.8 | 12.9 | 19.8 | 14.3 | 11.8 | 9.0 | 8.2 |
| EV / EBITDA | 32.4 | 39.2 | 37.6 | 29.5 | 34.6 | 73.7 | 27.9 | 39.9 | 28.9 | 25.3 |
| EV / free cash flow | 42.2 | 33.1 | 49.9 | 62.3 | 51.0 | 59.8 | 68.9 | 54.1 | 38.8 | 35.8 |
| Earnings yield | 1.6% | 0.9% | 1.5% | 2.2% | 1.9% | 0.8% | 2.2% | 1.2% | 2.2% | 1.8% |
| Free cash flow yield | 2.4% | 3.1% | 2.0% | 1.6% | 2.0% | 1.7% | 1.5% | 1.9% | 2.7% | 2.9% |
| Dividend yield | 0.4% | 0.6% | 0.4% | 0.4% | 0.4% | 0.3% | 0.5% | 0.6% | 0.9% | 1.1% |
| Shareholder yield (dividends + buybacks) | 0.8% | 4.0% | 1.1% | 0.5% | 1.5% | 0.5% | 1.0% | 0.8% | 0.9% | 1.1% |
| Share price at fiscal year-end | $70.65 | $51.45 | $71.65 | $81.63 | $86.66 | $112.56 | $66.02 | $52.12 | $36.99 | $29.38 |
| Per share | ||||||||||
| Revenue per share | $7.74 | $7.64 | $7.21 | $7.02 | $6.74 | $5.75 | $4.69 | $4.59 | $4.22 | $3.75 |
| Earnings per share | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.45 | $0.62 | $0.82 | $0.52 |
| Operating cash flow per share | $1.86 | $1.80 | $1.86 | $1.57 | $1.98 | $2.17 | $1.30 | $1.17 | $1.12 | $0.96 |
| Free cash flow per share | $1.68 | $1.61 | $1.47 | $1.34 | $1.71 | $1.90 | $0.97 | $1.00 | $0.98 | $0.86 |
| Cash per share | $1.69 | $1.02 | $0.95 | $1.26 | $1.51 | $1.43 | $1.72 | $1.07 | $1.19 | $1.05 |
| Book value per share | $13.43 | $12.01 | $12.87 | $12.15 | $10.37 | $9.65 | $8.76 | $7.49 | $7.09 | $6.34 |
| Tangible book value per share | $5.28 | $3.58 | $3.66 | $3.45 | $2.12 | $0.64 | $0.87 | −$0.94 | $0.23 | −$0.53 |
| Dividends per share | $0.32 | $0.32 | $0.31 | $0.31 | $0.31 | $0.31 | $0.31 | $0.31 | $0.32 | $0.32 |
| Capex per share | $0.18 | $0.19 | $0.39 | $0.24 | $0.27 | $0.27 | $0.33 | $0.16 | $0.14 | $0.10 |
| Debt per share | $1.84 | $2.78 | $2.61 | $2.81 | $1.99 | $2.60 | $2.75 | $3.25 | $2.29 | $2.33 |
| Shares outstanding | 157.0M | 159.7M | 160.8M | 161.9M | 164.1M | 161.9M | 157.6M | 155.6M | 152.2M | 150.0M |
| Change in shares outstanding | −1.7% | −0.7% | −0.7% | −1.4% | +1.3% | +2.7% | +1.3% | +2.2% | +1.5% | +0.5% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 9.0% | 3.7% | 8.3% | 15.6% | 16.7% | 9.5% | 18.0% | 8.6% | 12.3% | 8.4% |
| Return on invested capital (ROIC) | 8.8% | 3.4% | 8.2% | 12.6% | 14.7% | 13.6% | 8.6% | 7.8% | 11.3% | 8.1% |
| Return on assets (ROA) | 6.9% | 2.8% | 6.3% | 11.6% | 11.9% | 6.5% | 11.7% | 5.5% | 8.0% | 5.8% |
| Return on tangible assets | 13.0% | 6.1% | 13.7% | 23.2% | 28.9% | 17.5% | 29.3% | 16.8% | 22.8% | 14.7% |
| Free cash flow margin | 21.7% | 21.0% | 20.4% | 19.0% | 25.4% | 33.1% | 20.8% | 21.9% | 23.2% | 22.8% |
| Income quality (OCF / net income) | 1.61 | 3.92 | 1.78 | 0.89 | 1.20 | 2.51 | 0.89 | 1.89 | 1.36 | 1.86 |
| Financial health | ||||||||||
| Total debt | $289.1M | $444.1M | $419.5M | $455.0M | $326.0M | $420.6M | $433.5M | $505.2M | $347.9M | $349.9M |
| Cash & short-term investments | $264.7M | $162.2M | $152.9M | $204.3M | $247.0M | $231.6M | $270.9M | $166.0M | $181.8M | $157.7M |
| Net debt | $24.4M | $281.9M | $266.7M | $250.7M | $78.9M | $189.0M | $162.6M | $339.1M | $166.1M | $192.2M |
| Debt / equity | 0.14 | 0.23 | 0.20 | 0.23 | 0.19 | 0.27 | 0.31 | 0.43 | 0.32 | 0.37 |
| Debt / assets | 0.11 | 0.17 | 0.16 | 0.17 | 0.14 | 0.19 | 0.21 | 0.27 | 0.22 | 0.22 |
| Net debt / EBITDA | 0.07 | 1.30 | 0.85 | 0.55 | 0.19 | 0.76 | 0.43 | 1.60 | 0.83 | 1.06 |
| Current ratio | 4.55 | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 | 4.88 | 4.05 | 5.06 | 2.55 |
| Quick ratio | 3.35 | 2.38 | 2.75 | 3.50 | 2.64 | 2.59 | 3.92 | 3.15 | 3.97 | 2.11 |
| Interest coverage | 46.6 | 12.0 | 13.1 | 26.7 | 26.2 | 17.0 | 8.2 | 5.8 | 13.4 | 16.5 |
| Working capital | $580.7M | $432.5M | $458.0M | $493.0M | $429.5M | $358.3M | $414.3M | $310.6M | $319.7M | $209.9M |
| Invested capital | $2.13B | $2.20B | $2.34B | $2.22B | $1.78B | $1.75B | $1.54B | $1.50B | $1.25B | $1.14B |
| Tangible asset value | $829.4M | $572.3M | $589.1M | $559.1M | $347.4M | $112.2M | $136.3M | −$146.5M | $34.9M | −$80.2M |
| Net current asset value | $173.6M | −$30.8M | −$17.6M | −$50.7M | $11.8M | −$181.1M | −$125.5M | −$306.2M | −$115.7M | −$260.6M |
| Graham number | $18.71 | $11.15 | $17.40 | $21.95 | $19.67 | $13.72 | $16.94 | $10.20 | $11.46 | $8.57 |
| Graham net-net per share | −$0.27 | −$1.42 | −$1.31 | −$1.35 | −$0.79 | −$1.81 | −$1.47 | −$2.60 | −$1.31 | −$2.20 |
| Capital allocation | ||||||||||
| Dividends paid | $49.9M | $50.4M | $50.4M | $50.3M | $50.2M | $49.6M | $48.9M | $48.4M | $48.0M | $47.3M |
| Share buybacks (net) | $41.7M | $275.7M | $80.0M | $19.6M | $160.9M | $43.2M | $50.1M | $15.4M | $0 | $0 |
| Dividend payout ratio | 27.4% | 68.7% | 30.0% | 17.6% | 18.4% | 35.3% | 21.3% | 50.3% | 38.3% | 61.2% |
| Dividends + buybacks / free cash flow | 34.8% | 127.1% | 55.3% | 32.3% | 75.3% | 30.1% | 64.5% | 40.8% | 32.1% | 36.9% |
| Capex / revenue | 2.4% | 2.5% | 5.4% | 3.4% | 4.1% | 4.8% | 7.0% | 3.6% | 3.3% | 2.7% |
| Capex / operating cash flow | 9.9% | 10.8% | 21.0% | 15.0% | 13.8% | 12.6% | 25.2% | 14.0% | 12.3% | 10.6% |
| Capex / depreciation | 0.30 | 0.28 | 0.56 | 0.36 | 0.44 | 0.50 | 0.63 | 0.33 | 0.32 | 0.25 |
| Stock-based compensation / revenue | 3.4% | 3.3% | 3.3% | 3.5% | 3.8% | 5.3% | 4.4% | 4.5% | 4.4% | 2.6% |
| R&D / revenue | 7.8% | 8.2% | 8.3% | 8.1% | 7.9% | 7.6% | 8.8% | 8.7% | 8.6% | 9.5% |
| SG&A / revenue | 37.2% | 34.0% | 39.9% | 33.3% | 33.7% | 34.9% | 35.3% | 37.0% | 37.4% | 35.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 64.2 | 67.1 | 72.4 | 66.3 | 56.1 | 52.5 | 64.2 | 65.9 | 67.3 | 68.1 |
| Days of inventory on hand | 169.0 | 156.9 | 164.7 | 155.6 | 134.8 | 134.6 | 138.7 | 134.1 | 126.2 | 113.5 |
| Days payables outstanding | 22.8 | 26.9 | 29.8 | 29.6 | 33.1 | 32.1 | 28.1 | 60.5 | 69.6 | 36.3 |
| Cash conversion cycle (days) | 210.4 | 197.1 | 207.3 | 192.3 | 157.9 | 155.0 | 174.9 | 139.4 | 123.9 | 145.4 |
| Receivables turnover | 5.69 | 5.44 | 5.04 | 5.50 | 6.50 | 6.95 | 5.68 | 5.54 | 5.42 | 5.36 |
| Payables turnover | 16.00 | 13.57 | 12.23 | 12.32 | 11.04 | 11.36 | 13.00 | 6.03 | 5.24 | 10.05 |
| Inventory turnover | 2.16 | 2.33 | 2.22 | 2.35 | 2.71 | 2.71 | 2.63 | 2.72 | 2.89 | 3.21 |
| Asset turnover | 0.46 | 0.46 | 0.43 | 0.46 | 0.49 | 0.43 | 0.38 | 0.41 | 0.41 | 0.42 |
| Average receivables | $213.7M | $224.1M | $229.9M | $206.5M | $170.0M | $134.0M | $130.0M | $128.9M | $118.6M | $105.1M |
| Average payables | $26.0M | $31.6M | $31.8M | $29.8M | $31.6M | $26.2M | $19.6M | $39.9M | $40.2M | $18.8M |
| Average inventory | $192.6M | $184.6M | $175.7M | $156.4M | $128.9M | $110.0M | $97.1M | $88.3M | $72.9M | $58.6M |
| Intangibles / total assets | 47.7% | 52.6% | 54.7% | 53.3% | 59.0% | 64.5% | 61.4% | 69.6% | 65.5% | 66.2% |
Computed from TECH's annual financial statements (latest annual report filed August 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TECH valuation and financial ratios
At the end of fiscal 2026 (June 30, 2026), Bio-Techne traded at 61.0 times earnings, against a 10-year median of 59.0. Based on the latest twelve months, the trailing P/E is 62.6 and the forward P/E is 34.6. Bio-Techne earned a return on equity of 9.0% and a return on invested capital of 8.8% in fiscal 2026. It ended the year with $289.1 million of debt and $264.7 million in cash and short-term investments, net debt of $24.4 million. It returned $91.6 million to shareholders: $49.9 million in dividends and $41.7 million in share buybacks, 35% of free cash flow. The share count rose 4.7% from 150.0M to 157.0M over 9 years.
See the TECH income statement, the TECH chart for price history, or the TECH stock overview for the latest quote and news.
TECH key metrics FAQ
What is Bio-Techne's P/E ratio?
Bio-Techne's trailing P/E ratio is 62.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 34.6. At the end of fiscal 2026 it was 61.0, compared with a 10-year median of 59.0.
What is Bio-Techne's EV/EBITDA?
Bio-Techne's enterprise value was 32.4 times EBITDA at the end of fiscal 2026 (enterprise value $11.1 billion, EBITDA $343.4 million); the current EV/EBITDA is 32.8.
What is Bio-Techne's return on equity?
Bio-Techne's return on equity (ROE) was 9.0% in fiscal 2026: net income of $181.9 million on average shareholders' equity of $2.0 billion.
What is Bio-Techne's ROIC?
Bio-Techne's return on invested capital was 8.8% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Bio-Techne have?
Bio-Techne had total debt of $289.1 million at the end of fiscal 2026, a debt-to-equity ratio of 0.14 and $24.4 million of net debt (0.07 times EBITDA).
What is Bio-Techne's dividend yield?
Bio-Techne's forward dividend yield is 0.44%. Bio-Techne paid $49.9 million in dividends in fiscal 2026 ($0.32 per share), a payout ratio of 27.4%.
Does Bio-Techne buy back its shares?
Yes. Bio-Techne spent $41.7 million on net share repurchases in fiscal 2026 Shares outstanding changed −1.7% over the year, to 157.0M..
What is Bio-Techne's free cash flow yield?
Bio-Techne generated $263.2 million of free cash flow in fiscal 2026, a free cash flow yield of 2.4% on its market value at year-end ($11.1 billion).
What is Bio-Techne's current ratio?
Bio-Techne's current ratio was 4.55 at the end of fiscal 2026: current assets were 4.55 times current liabilities.